A Prospective, Vehicle Controlled, Double Blind, Multicenter, Randomized, Phase II Study of B244 Delivered as a Topical Spray to Determine Safety and Efficacy in Subjects With Mild to Moderate Atopic Dermatitis
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 16 Jan 2019
At a glance
- Drugs B 244 (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions
- Sponsors AOBiome
- 08 Jan 2019 Planned End Date changed from 1 Apr 2019 to 1 Jul 2019.
- 08 Jan 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Apr 2019.
- 08 Jan 2019 Status changed from recruiting to active, no longer recruiting.